BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lamers C, Mastellos DC, Ricklin D, Lambris JD. Compstatins: the dawn of clinical C3-targeted complement inhibition. Trends in Pharmacological Sciences 2022. [DOI: 10.1016/j.tips.2022.01.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Jiang J, Wang Y, Deng M. New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1054006] [Reference Citation Analysis]
2 Schmidt CQ, Smith RJH. Protein therapeutics and their lessons: Expect the unexpected when inhibiting the multi‐protein cascade of the complement system. Immunological Reviews 2022. [DOI: 10.1111/imr.13164] [Reference Citation Analysis]
3 Dreismann AK, Hallam TM, Tam LC, Nguyen CV, Hughes JP, Ellis S, Harris CL. Gene targeting as a therapeutic avenue in diseases mediated by the complement alternative pathway. Immunological Reviews 2022. [DOI: 10.1111/imr.13149] [Reference Citation Analysis]
4 Gabrili JJM, Villas-boas IM, Pidde G, Squaiella-baptistão CC, Woodruff TM, Tambourgi DV. Complement System Inhibition Modulates the Inflammation Induced by the Venom of Premolis semirufa, an Amazon Rainforest Moth Caterpillar. IJMS 2022;23:13333. [DOI: 10.3390/ijms232113333] [Reference Citation Analysis]
5 Zarantonello A, Revel M, Grunenwald A, Roumenina LT. C3-dependent effector functions of complement. Immunol Rev 2022. [PMID: 36271889 DOI: 10.1111/imr.13147] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Kolev M, Barbour T, Baver S, Francois C, Deschatelets P. With complements: C3 inhibition in the clinic. Immunol Rev 2022. [PMID: 36161656 DOI: 10.1111/imr.13138] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Lamers C, Xue X, Smieško M, van Son H, Wagner B, Berger N, Sfyroera G, Gros P, Lambris JD, Ricklin D. Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitors. Nat Commun 2022;13:5519. [PMID: 36127336 DOI: 10.1038/s41467-022-33003-7] [Reference Citation Analysis]
8 Mastellos DC, Lambris JD. Recent developments in C3-targeted complement therapeutics. Semin Immunol 2022;:101645. [PMID: 35915008 DOI: 10.1016/j.smim.2022.101645] [Reference Citation Analysis]
9 Kim BJ, Liu T, Mastellos DC, Lambris JD. Emerging opportunities for C3 inhibition in the eye. Semin Immunol 2022;:101633. [PMID: 35787973 DOI: 10.1016/j.smim.2022.101633] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Risitano AM, Peffault de Latour R, Marano L, Frieri C. Discovering C3 targeting therapies for paroxysmal nocturnal hemoglobinuria: Achievements and pitfalls. Semin Immunol 2022;:101618. [PMID: 35764467 DOI: 10.1016/j.smim.2022.101618] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Kajikawa T, Mastellos DC, Hasturk H, Kotsakis GA, Yancopoulou D, Lambris JD, Hajishengallis G. C3-targeted host-modulation approaches to oral inflammatory conditions. Semin Immunol 2022;:101608. [PMID: 35691883 DOI: 10.1016/j.smim.2022.101608] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Lamers C. Overcoming the shortcomings of peptide-based therapeutics. Future Drug Discovery 2022;4. [DOI: 10.4155/fdd-2022-0005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]